Global Allergic Conjunctivitis Market Report by Disease Type, Drug class, Distribution Channel, Countries and Company Analysis, 2024-2032

Allergic Conjunctivitis Market is expected to reach US$ 2.40 Billion by 2032 from US$ 1.96 Billion in 2023, with a CAGR of 2.27% during 2024-2032.

Allergic conjunctivitis interchangeably is also known as Ocular allergy (OA). It is a common immunological hypersensitivity disorder affecting numerous populations. In recent years, allergic conjunctivitis has been increasing in frequency, with symptoms of itching, redness, and swelling globally that significantly impact an individual’s quality of life. Besides, allergic conjunctivitis is an often under diagnosed and undertreated health problem because very few patients with allergic conjunctivitis symptoms seek medical attention, whereas most patients manage with over-the-counter medications and complementary no pharmacological remedies.

Generally, conjunctivitis is self-diagnosable, and there is the least need to undergo any diagnostic test for this disease. Thus, the incidence of allergic conjunctivitis is expected to contribute to the market's growth during the forecast period. As per another NIH article published in February 2021, viral and bacterial conjunctivitis are the two common forms of infectious conjunctivitis, with viral infection responsible for up to 80% of all acute conjunctivitis cases and bacterial infection accounting for between 50-75% of cases of infectious conjunctivitis in children. According to the same source, countries like China also have a high incidence of conjunctivitis. Moreover, as per the BMC article published in March 2022, the average annual hemorrhagic conjunctivitis incidence was 3.58/100,000 in mainland China. The rising incidence of hemorrhagic conjunctivitis is expected to drive the demand for conjunctivitis treatment, thereby contributing to market growth.

Increase in patient population of allergic conjunctivitis worldwide and escalating demand for healthcare services is expected to majorly drive the market growth. In addition, many key market players are focusing on R&D activities to develop drugs for allergic conjunctivitis as patient population is increasing, which also drives the allergic conjunctivitis market growth.

As per the Nature article published in April 2022, approximately 10% of the sample population had allergic conjunctivitis. In India, the prevalence of allergic conjunctivitis was 12.22% among those aged between five and 15 years. Also, the NCBI article published in January 2021 mentioned that more than half of the patients report daily symptoms as seasonal or perennial and around 75% consider their symptoms to be severe. The same source also mentioned that there were between 1.2 and 10.6 cases of vernal keratoconjunctivitis per 10,000 individuals in Europe. Such incidence of allergic conjunctivitis is expected to drive the demand for effective treatment, contributing to the growth of the studied segment.

Furthermore, rise in exposure to pollutants and chemicals causes allergic conjunctivitis and is also expected to propel the allergic conjunctivitis market forecast. However, adverse reaction of allergic conjunctivitis medications can impede the growth of the market. Conversely, increase in awareness about the disease creates allergic conjunctivitis market opportunity for the key players to invest.

North America allergic conjunctivitis market

North America is expected to dominate the market, owing to factors such as the easy availability of effective treatment products and high awareness among consumers regarding conjunctivitis in the region. As per the National Library Medicine article published in February 2020, conjunctivitis affects more than 6 million people across the United States every year. The estimated cost for the disease is around USD 377 million to USD 857 million per year. Conjunctivitis is found to be the most frequent disease in the country and affects 15% to 40% of the population, and is seen frequently in spring and summer.

Also, the NCBI article published in January 2021 mentioned that seasonal or perennial allergic conjunctivitis is the most prevalent form of allergic conjunctivitis, with more than 95% of ocular allergy cases in the United States. It is observed in both sexes and affects between 15% and 40% of the population. Such prevalence of conjunctivitis in the United States is expected to drive the demand for effective treatment, thereby contributing to the market's growth during the forecast period.

Due to better healthcare services and the high number of people suffering from conjunctivitis in the United States, the market is expected to hold the largest share shortly. Also, the high prevalence of conjunctivitis in Canada is expected to contribute to the market's growth over the forecast period. As per the BMC article published in October 2022, it is estimated that 21% of Canadians have dry eyes. Such prevalence of conjunctivitis is expected to contribute to market growth in Canada.

Allergic Conjunctivitis Industry Analysis

The Allergic conjunctivitis competitive landscape includes an analysis of global and local companies which hold market shares and are well known, including Ajanta Pharma Limited, Akorn Operating Company LLC, Alembic Pharmaceutical Ltd., Cipla Inc., Indoco Remedies Ltd., Johnson & Johnson, Novartis AG, Ocular Therapeutix, Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Disease Types - Global Allergic Conjunctivitis Market is divided into 2 viewpoints

1. Seasonal ALLERGIC Conjunctivitis (SAC)
2. Perennial Allergic Conjunctivitis (PAC)

Drugs Class - Global Allergic Conjunctivitis Market is divided into 3 viewpoints

1. Antihistamines & Mast Cell Stabilizers
2. Corticosteroids
3. Others

Distribution Channels - Global Allergic Conjunctivitis Market is divided into 4 viewpoints

1. Hospital Pharmacies
2. Online Pharmacies
3. Retail Pharmacies & Drug Stores
4. Others

Countries - Market is divided into 25 country Allergic Conjunctivitis Industry

North America

1. United States
2. Canada

Europe

1. France
2. Germany
3. Italy
4. Spain
5. United Kingdom
6. Belgium
7. Netherlands
8. Turkey

Asia Pacific

1. China
2. Japan
3. India
4. Australia
5. South Korea
6. Thailand
7. Malaysia
8. Indonesia
9. New Zealand

Latin America

1. Brazil
2. Mexico
3. Argentina

Middle East & Africa

1. South Africa
2. Saudi Arabia
3. United Arab Emirates

Company Insights:

1. Overview
2. Operating business segments
3. Product portfolio & Product Launch in Last 1 Year
4. Recent Developments
5. Revenue

Companies Covered:

1. Ajanta Pharma Limited
2. Akorn Operating Company LLC
3. Alembic Pharmaceutical Ltd.
4. Cipla Inc.
5. Indoco Remedies Ltd.
6. Johnson & Johnson
7. Novartis AG
8. Ocular Therapeutix, Inc.
9. Sun Pharmaceutical Industries Ltd.
10. Teva Pharmaceutical Industries Ltd.